Amicus Therapeutics (FOLD) +9.6% premarket after it says a preliminary study of its treatment...

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Amicus Therapeutics (FOLD) +9.6% premarket after it says a preliminary study of its treatment for Pompe disease showed positive results; AT2220-enzyme replacement therapy co-administration increased pompe enzyme activity in first three dose cohorts in the phase 2 study.